222 related articles for article (PubMed ID: 20527894)
1. Ruthenium polypyridyl complexes that induce mitochondria-mediated apoptosis in cancer cells.
Chen T; Liu Y; Zheng WJ; Liu J; Wong YS
Inorg Chem; 2010 Jul; 49(14):6366-8. PubMed ID: 20527894
[TBL] [Abstract][Full Text] [Related]
2. Ruthenium polypyridyl complexes as inducer of ROS-mediated apoptosis in cancer cells by targeting thioredoxin reductase.
Luo Z; Yu L; Yang F; Zhao Z; Yu B; Lai H; Wong KH; Ngai SM; Zheng W; Chen T
Metallomics; 2014 Aug; 6(8):1480-90. PubMed ID: 24823440
[TBL] [Abstract][Full Text] [Related]
3. Ruthenium complexes containing bis-benzimidazole derivatives as a new class of apoptosis inducers.
Li L; Wong YS; Chen T; Fan C; Zheng W
Dalton Trans; 2012 Jan; 41(4):1138-41. PubMed ID: 22159211
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175.
Hayward RL; Schornagel QC; Tente R; Macpherson JS; Aird RE; Guichard S; Habtemariam A; Sadler P; Jodrell DI
Cancer Chemother Pharmacol; 2005 Jun; 55(6):577-83. PubMed ID: 15726367
[TBL] [Abstract][Full Text] [Related]
5. Cellular uptake, cytotoxicity, and metabolic profiling of human cancer cells treated with ruthenium(II) polypyridyl complexes [Ru(bpy)2(N--N)]Cl2 with N--N=bpy, phen, dpq, dppz, and dppn.
Schatzschneider U; Niesel J; Ott I; Gust R; Alborzinia H; Wölfl S
ChemMedChem; 2008 Jul; 3(7):1104-9. PubMed ID: 18425738
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial fragmentation is an important cellular event induced by ruthenium(II) polypyridyl complexes in osteosarcoma cells.
Du Y; Fu X; Li H; Chen B; Guo Y; Su G; Zhang H; Ning F; Lin Y; Mei W; Chen T
ChemMedChem; 2014 Apr; 9(4):714-8. PubMed ID: 24403015
[TBL] [Abstract][Full Text] [Related]
7. Novel ruthenium complex K2[Ru(dmgly)Cl4].2H2O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes.
Djinović V; Momcilović M; Grgurić-Sipka S; Trajković V; Mostarica Stojković M; Miljković D; Sabo T
J Inorg Biochem; 2004 Dec; 98(12):2168-73. PubMed ID: 15541507
[TBL] [Abstract][Full Text] [Related]
8. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
9. Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents.
Cini R; Tamasi G; Defazio S; Corsini M; Zanello P; Messori L; Marcon G; Piccioli F; Orioli P
Inorg Chem; 2003 Dec; 42(24):8038-52. PubMed ID: 14632524
[TBL] [Abstract][Full Text] [Related]
10. Arene ruthenium complexes as anticancer agents.
Süss-Fink G
Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
[TBL] [Abstract][Full Text] [Related]
11. Bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) as a novel apoptosis-inducing anticancer agent.
Narla RK; Dong Y; D'Cruz OJ; Navara C; Uckun FM
Clin Cancer Res; 2000 Apr; 6(4):1546-56. PubMed ID: 10778988
[TBL] [Abstract][Full Text] [Related]
12. Ruthenium(II) polypyridyl complexes: cellular uptake, cell image and apoptosis of HeLa cancer cells induced by double targets.
Yu Q; Liu Y; Xu L; Zheng C; Le F; Qin X; Liu Y; Liu J
Eur J Med Chem; 2014 Jul; 82():82-95. PubMed ID: 24878637
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, antitumor activity and structure-activity relationships of a series of Ru(II) complexes.
Liu J; Zheng W; Shi S; Tan C; Chen J; Zheng K; Ji L
J Inorg Biochem; 2008 Feb; 102(2):193-202. PubMed ID: 17825915
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
[TBL] [Abstract][Full Text] [Related]
15. A novel phenotype-based approach for systematically screening antiproliferation metallodrugs.
Wang YH; Cheng CC; Lee WJ; Chiou ML; Pai CW; Wen CC; Chen WL; Chen YH
Chem Biol Interact; 2009 Nov; 182(1):84-91. PubMed ID: 19682442
[TBL] [Abstract][Full Text] [Related]
16. DNA binding, cytotoxicity, and apoptotic-inducing activity of ruthenium(II) polypyridyl complex.
Zhang P; Chen J; Liang Y
Acta Biochim Biophys Sin (Shanghai); 2010 Jul; 42(7):440-9. PubMed ID: 20705582
[TBL] [Abstract][Full Text] [Related]
17. Chiral ruthenium complexes induce apoptosis of tumor cell and interact with bovine serum albumin.
Yuan F; Chen X; Liu Y; Zhang T; Sun D; Liu J
Chirality; 2012 Feb; 24(2):174-80. PubMed ID: 22180296
[TBL] [Abstract][Full Text] [Related]
18. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
19. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
[TBL] [Abstract][Full Text] [Related]
20. Anticancer activity of tetracationic arene ruthenium metalla-cycles.
Barry NP; Edafe F; Therrien B
Dalton Trans; 2011 Jul; 40(27):7172-80. PubMed ID: 21660364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
